Analysis of the frequency of TRBJ segment usage showed that WAS patients had decreased usage of TRBJ2-1 (among both CD4+ and CD8+ cells) and an increased usage of TRBJ2-6 among CD8+ lymphocytes (Figure 5B). This evidence concerns the gene CD4 and Wiskott-Aldrich syndrome.